CAMBRIDGE, Mass.--(BUSINESS WIRE)--Samyang Biopharm USA, Inc. (https://us.samyangbiopharm.com) a global biotech subsidiary of the Samyang Holdings Corp. (https://samyangbiopharm.com/eng), announced today that Eun-Ju Ryu has been appointed President of Samyang Biopharm USA, end of Jan. 2022.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Samyang Biopharm USA, Inc. (https://us.samyangbiopharm.com) a subsidiary of Samyang Holdings Corp. (https://samyangbiopharm.com/eng), announced today that the company has entered into a research collaboration with the Spanish National Research Council (CSIC), a state agency for scientific research and technological development. The two organizations will work together to study the effect of NKG2D-ligand-containing vesicles and Samyang’s proprietary monoclonal antibody, SYB-010, on NKG2D receptor expression and NK cell function. Financial terms of the agreement were not released.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Samyang Biopharm USA, Inc. (https://us.samyangbiopharm.com) a global biotech subsidiary of the Samyang Holdings Pharmaceuticals Corp. (https://samyangbiopharm.com/eng), announced today that the company has entered into a three-year research collaboration with Dr. Hyun-Sung Lee, Assistant Professor of Surgery and Director of the Systems Onco-Immunology Laboratory (SOIL) at Baylor College of Medicine. Samyang has awarded Dr. Lee a sponsored research grant which will utilize the capabilities of his laboratory to investigate the potential role of SYB-010, Samyang’s lead Immuno-Oncology asset, in sensitizing the tumor-immune microenvironment to immune checkpoint inhibitors.
CAMBRIDGE, Mass. & SEOUL, South Korea--(BUSINESS WIRE)--Samyang Biopharm USA, Inc. (https://us.Samyangbiopharm.com) a global biotech subsidiary of the Samyang Pharmaceuticals Corp. (https://Samyangbiopharm.com/eng), announced today that the company has established the “Samyang CRS Award in Honor of Sung Wan Kim.” The announcement was made at the 2020 annual meeting of the Controlled Release Society where the inaugural award will be presented next year at the 2021 conference.
Samyang Biopharm USA, Inc and CanCure LLC Announce Global Strategic Collaboration to Advance Novel Immuno-Oncology Therapeutic
Executives from Samyang Biopharm USA, Inc. and CanCure LLC gathered recently to celebrate the global partnership between the two companies to develop and advance a novel Imuno-Oncology Therapeutic for the treatment of cancer. Under the terms of the agreement, CanCure grants Samyang worldwide rights for the development, manufacturing and commercialization of SYB-010 (formerly CuraB-10), a first-in-class, immune stimulatory monoclonal antibody. Samyang Biopharm USA plans to file an IND in 2021, with a goal of starting SYB-010 clinical trials shortly after IND approval. Pictured in front row, L-R: Helen Hyun Jung Lee, M.D., President/CEO, Samyang Biopharm USA and Jennifer Wu, Ph.D., Founder and President, CanCure. Back row: David Brooks, M.D., Ph.D., VP, Clinical Development, Samyang Biopharm USA, Jeff Lange, VP, Business Development, Samyang Biopharm USA, and Grant Risdon, PhD. Senior Director, Business Development, CanCure. (Photo: Business Wire)
Samyang Biopharm USA, Inc. (https://us.samyangbiopharm.com) a global biotech subsidiary of the Samyang Pharmaceuticals Corp. (https://samyangbiopharm.com/eng), announced today that the company has entered into a worldwide licensing agreement with CanCure LLC. Financial terms of the agreement were not disclosed.
Sorrento Acquires South American Rights To Cynviloq™
At Phyton Biotech we develop and apply sustainable specialty fermentation solutions. As global leaders in Plant Cell Fermentation (PCF®) technology, Phyton Biotech strives to provide solutions to customers seeking vital active compounds. We have state-of-the-art, GMP certified PCF® facilities located in both Canada and Germany and operate the world’s largest Plant Cell Fermentation (PCF®) technology facility with more than 200,000 litres of fermentation capacity.